Taysha Gene Therapies, Inc. (TSHA)
6.02
-0.18
(-2.90%)
USD |
NASDAQ |
Aug 26, 16:00
6.14
+0.12
(+1.99%)
After-Hours: 20:00
Taysha Gene Therapies Enterprise Value : 1.560B for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 1.560B |
| August 25, 2026 | 1.618B |
| August 24, 2026 | 1.544B |
| August 21, 2026 | 1.583B |
| August 20, 2026 | 1.589B |
| August 19, 2026 | 1.693B |
| August 18, 2026 | 1.615B |
| August 17, 2026 | 1.622B |
| August 14, 2026 | 1.537B |
| August 13, 2026 | 1.550B |
| August 12, 2026 | 1.685B |
| August 11, 2026 | 1.774B |
| August 10, 2026 | 1.674B |
| August 07, 2026 | 1.735B |
| August 06, 2026 | 1.664B |
| August 05, 2026 | 1.703B |
| August 04, 2026 | 1.618B |
| August 03, 2026 | 1.482B |
| July 31, 2026 | 1.508B |
| July 30, 2026 | 1.513B |
| July 29, 2026 | 1.426B |
| July 28, 2026 | 1.378B |
| July 27, 2026 | 1.404B |
| July 24, 2026 | 1.397B |
| July 23, 2026 | 1.498B |
| Date | Value |
|---|---|
| July 22, 2026 | 1.443B |
| July 21, 2026 | 1.446B |
| July 20, 2026 | 1.417B |
| July 17, 2026 | 1.540B |
| July 16, 2026 | 1.544B |
| July 15, 2026 | 1.615B |
| July 14, 2026 | 1.456B |
| July 13, 2026 | 1.352B |
| July 10, 2026 | 1.664B |
| July 09, 2026 | 1.739B |
| July 08, 2026 | 1.713B |
| July 07, 2026 | 1.716B |
| July 06, 2026 | 1.677B |
| July 02, 2026 | 1.726B |
| July 01, 2026 | 1.765B |
| June 30, 2026 | 1.817B |
| June 29, 2026 | 1.725B |
| June 26, 2026 | 1.613B |
| June 25, 2026 | 1.576B |
| June 24, 2026 | 1.786B |
| June 23, 2026 | 1.763B |
| June 22, 2026 | 1.668B |
| June 18, 2026 | 1.636B |
| June 17, 2026 | 1.570B |
| June 16, 2026 | 1.472B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 322.29M |
| Protalix Biotherapeutics, Inc. | 167.65M |
| Humacyte, Inc. | 175.48M |
| Agenus, Inc. | 616.24M |
| Amgen, Inc. | 281.36B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.64M |
| Total Expenses (Quarterly) | 46.64M |
| EPS Diluted (Quarterly) | -0.1264 |
| Earnings Yield | -7.18% |
| Normalized Earnings Yield | -6.932 |